sion of banked red blood cells (RBCs) has been associated with poor cardiovascular outcomes. Storage-induced alterations in RBC glycolytic flux, attenuated ATP export, and microvascular adhesion of transfused RBCs in vivo could contribute, but the underlying mechanisms have not been tested. We tested the novel hypothesis that improving deoxygenation-induced metabolic flux and the associated intracellular ATP generation in stored RBCs (sRBCs) results in an increased extracellular ATP export and suppresses microvascular adhesion of RBCs to endothelium in vivo following transfusion. We show deficient intracellular ATP production and ATP export by human sRBCs during deoxygenation (impairments ϳ42% and 49%, respectively). sRBC pretreatment with a solution containing glycolytic intermediate/purine/phosphate precursors (i.e., "PIPA") restored deoxygenation-induced intracellular ATP production and promoted extracellular ATP export (improvement ϳ120% and 50%, respectively). In a nude mouse model of transfusion, adhesion of human RBCs to the microvasculature in vivo was examined. Only 2% of fresh RBCs (fRBCs) transfused adhered to the vascular wall, compared with 16% of sRBCs transfused. PIPA pretreatment of sRBCs significantly reduced adhesion to just 5%. In hypoxia, adhesion of sRBCs transfused was significantly augmented (up to 21%), but not following transfusion of fRBCs or PIPA-treated sRBCs (3.5% or 6%). Enhancing the capacity for deoxygenation-induced glycolytic flux within sRBCs increases their ability to generate intracellular ATP, improves the inducible export of extracellular anti-adhesive ATP, and consequently suppresses adhesion of stored, transfused RBCs to the vascular wall in vivo.
RED BLOOD CELL (RBC) TRANSFUSION is a common and sometimes lifesaving medical practice, but accumulating evidence questions both the criteria indicating a transfusion requirement and the relative benefits of transfusing RBCs later in their storage period (42-day maximum duration in the United States) (2, 5, 16 -18, 20) . Banking of RBCs elicits a "storage lesion" characterized by time-dependent metabolic and biochemical alterations including diminished intracellular ATP and 2,3-DPG, and a loss of bioactive nitric oxide (NO) derivatives (2, 30, 31, 33) . Functionally, longer-banked RBCs are less deformable, promote hypoxic vasodilation poorly, and adhere excessively to blood vessel walls (2, 30, 31, 43) . Such effects from RBC banking could contribute to the disappointing, adverse clinical outcomes (e.g., increased hospital days and duration of mechanical ventilation, multiple organ failure, transfusion-related lung injury, mortality) often associated with transfusion of longer-stored RBCs (20, 31, 32) .
Remarkably, RBCs rely solely on glycolysis for intracellular ATP production, and hemoglobin (Hb) deoxygenation is a primary and potent activator of glycolytic flux within the RBC (4, 25, 39) . Glycolytic enzymes normally bound to the RBC cytoplasmic domain of the membrane protein band 3 (cdb3; band 3 is also called anion exchanger-1) during R-state Hb conformation are liberated upon T-state Hb transition, thus shifting RBC metabolism from the pentose phosphate pathway (PPP; supporting generation of NADPH) toward the Embden Myerhof pathway (glycolytic production of NADH and ATP) (4, 23, 25) . In this regard, coupling of RBC energy metabolism and O 2 -sensing is directly governed by O 2 -dependent regulation of binding of Hb by cdb3 (23, 25) . Increasing intracellular ATP production, particularly in hypoxia, is essential for ion transport processes, phosphorylation reactions, and the production of reducing equivalents. These ATP-dependent events in turn regulate osmotic balance, cellular integrity, and redox reactions (9, 35, 39) .
Over a decade of investigation now indicates that ATP is more than a mere intracellular energy molecule, but also undergoes regulated export to assist in controlling extracellular processes (3, 7) . In RBCs, functional glycolysis and cdb3 activity are two key factors regulating the hypoxia-sensitive controlled export of ATP (3, 13) . We recently demonstrated that stored RBCs (sRBCs) exhibit a marked impairment in deoxygenation-induced ATP export (43) . Furthermore, we observed that extracellular ATP acts as an anti-adhesive molecule and that RBCs deficient in ATP export are excessively adherent to the vascular endothelium (43) . Given the cumulative evidence demonstrating that glycolytic inhibition significantly blunts ATP export from fresh RBCs (fRBCs) (13) and that RBC band 3 content is lowered with RBC storage (22) , we questioned whether banked RBCs are functionally defective in glycolysis-mediated ATP production in response to deoxygenation and whether restoration of ATP production and export might attenuate RBC adhesion after transfusion.
We performed a series of experiments to investigate 1) the capacity for sRBCs to increase glycolytic activity and ATP generation in hypoxia, 2) the impact of raising intracellular ATP content of banked RBCs on the controlled release of ATP from RBCs, and 3) how these interventions influence adhesion of transfused RBCs to the microvasculature in vivo. Accordingly, we first tested the hypothesis that banked RBCs are defective in the control of low O 2 -stimulated glycolysis (evidenced via intracellular ATP measures) and that RBC supplementation with an FDA-approved additive solution containing glycolytic intermediate/purine/phosphate precursors (i.e., pyruvate, inosine, inorganic phosphate, and adenine; here called "PIPA") reverses this deficiency. Second, we tested the hypothesis that augmentation of hypoxia-mediated increases in intracellular ATP of banked RBCs is associated with an improvement in controlled, hypoxia-triggered ATP export. Third, we tested the hypothesis that banked human RBCs are markedly adhesive in vivo following transfusion and that pretransfusion treatment of RBCs with glycolytic intermediate/purine/ phosphate precursors known to increase both intracellular ATP and the inducible extracellular release of ATP attenuates storage-mediated adhesion of transfused RBCs. To do so, we used an FDA-approved additive solution, PIPA, rich in RBC metabolic precursors and used a murine model of RBC transfusion to examine human RBC function in vivo.
METHODS

Collection, preparation, and treatment of RBCs. With Institutional
Review Board approval and after written informed consent was obtained, venous blood was obtained by venipuncture of the antecubital vein of healthy volunteers into Vacutainer tubes containing sodium heparin (158 USP units). fRBCs were isolated by centrifugation (500 g at 4°C for 10 min), and the plasma and buffy coat were removed. Packed RBCs were resuspended and washed three times in physiological salt solution (PSS; 4.7 mM KCl, 2.0 mM CaCl 2, 1.2 mM MgSO4, 140.5 mM NaCl, 21.0 mM Tris-base, and 5.5 mM glucose with 0.5% BSA, pH adjusted to 7.4). This method of isolation yields a RBC suspension devoid of platelets and fewer than one leukocyte per 50 high-power fields (15, 37) .
Stored, leukoreduced RBCs were obtained from banked RBC unit segments in their last week of storage (36 -42 days; Duke Medical Center Transfusion Services). The additive solution used for sRBCs was most frequently additive solution-3, with the remainder in additive solution-1. Aliquots were washed three times in excess PSS and resuspended. To provide sRBCs with glycolytic substrate supplementation, a formula equivalent to Rejuvesol [here designated "PIPA", and consisting of (in mmol/l) 100 sodium pyruvate, 99.9 inosine, 70.4 dibasic sodium phosphate, 29 monobasic sodium phosphate, and 5 adenine, pH 7.2] was generated according to published methods and incubated with packed sRBCs at a ratio of 1:4 for 60 min at 37°C (26) . PIPA is believed to support glycolytic flux through 1) the conversion of exogenous inosine toward ribose-5-phosphate, which can then be converted to the key glycolytic intermediates, fructose-6-phosphate, and glyceraldehyde-3-phosphate, 2) production of NAD, which is essential to both inosine metabolism and the generation of ATP/2,3-DPG via production of 1,3-DPG, via conversion of pyruvate to lactate, and 3) the provision of exogenous adenine and inorganic phosphates as substrates for nucleotide synthesis (26, 27) . Given the potential in vivo toxicity of certain agents within the PIPA formula, treated RBCs were again washed with PSS before study. All studies on isolated RBCs were performed on the day of acquisition to minimize any alterations associated with laboratory processing.
RBC deoxygenation and measurement of extracellular ATP. The purpose of this procedure was to determine ATP export in response to RBC Hb deoxygenations. A 10% RBC suspension was placed in a rotating-bulb tonometer and warmed to 37°C (Eschweiler, Germany). To produce a normoxic isocapnic environment, RBCs were exposed to a blend of the gases 18% O 2, 5.8% CO2, and balance N2.
Progressive RBC deoxygenation was induced by lowering O2 to 5%, 2.5%, and 1%, maintaining a stable CO 2 at 5.8% (balance N2). Gases were blended in a custom gas blender (MCQ Gas Blender Series 100; Italy) for 10 min, humidified, and introduced into the enclosed tonometer to produce graded degrees of RBC deoxygenation. Deoxygenation was confirmed by blood gas analysis (Siemens Rapid Point 405 Series Automatic Blood Gas System; Los Angeles, CA) (15) .
ATP was measured via luciferin-luciferase technique with light emission during the reaction detected by a luminometer. A sample of 10% Hct was diluted 250-fold, and a 200 l RBC suspension (0.04% Hct) was injected into a cuvette containing 100 l of 10 mg/ml crude firefly tail extract (Sigma) and 100 l of 0.5 mg/mL D-luciferin (RPI) mixed in PBS. Extracellular ATP was normalized to a cell count of 4 ϫ 10 8 cells/ml. For intracellular ATP measurements, a 50 l sample of RBC suspension (10% Hct) was obtained, diluted 600-fold, lysed with water, and immediately analyzed for ATP and Hb. Intracellular ATP was normalized to [Hb] by spectrophotometry (BMG Labtech). A standard curve for ATP (Calbiochem) was obtained in the RBC suspension for each individual experiment. To confirm that ATP export was not due to hemolysis, RBC suspension aliquots acquired for ATP analysis were analyzed for cell free [Hb] similar to previous reports (15, 37, 43) .
Mouse window-chamber surgery and model. Mouse windowchamber surgery was performed to enable in vivo RBC and microvascular function assessment. Nude mice 9 -12 wk of age were anesthetized with 100 mg/kg and 10 mg/kg ketamine/xylazine mixture by intraperitoneal injection and received surgical placement of a dorsal skin window chamber, as previously detailed (29, 42) . Briefly, mice placed on a temperature-controlled mat were cleaned and disinfected with chlorhexidine solution and alcohol. Under a surgical hood, mice were placed on a sterile surgical stage, and a dorsal skin-fold was made by suturing the midline of the dorsum to a C clamp attached to a hanger. A 12-mm diameter flap of skin was dissected away from the surface of the dorsal skin flap, leaving a fascial plane with its associated vasculature. The opposite side of the skin flap of the mouse was left intact. After the skin-fold dissection, an apposed pair of titanium window frames were mounted and sutured to the skin flap. The circular incision was then aligned with the hole in the titanium frame, and a 12-mm glass cover was placed over the circular incision. Immediately upon completion of the surgery, each mouse received an injection of 0.05 mg/kg buprenorphine subcutaneously. Mice were studied 3-6 days after surgery to allow adequate wound healing.
RBC transfusion and oxygen manipulation protocol. The purpose of this protocol was to examine in vivo the functional response of RBC-blood vessel interactions caused by the transfusion of human RBCs. Therefore, to prevent tissue rejection complications, nude mice were used as transfusion recipients as described (43) . Mice were initially anesthetized with 4% isoflurane (inhaled) in an induction chamber. They were subsequently placed on a 37°C temperaturecontrolled heating pad, anesthetized with 2% inhaled isoflurane via nose cone breathing 100% O2, and monitored for breathing rate and response to toe pinch to assess the plane of anesthesia.
The transfusion and oxygen manipulation protocol is as follows. Ten minutes after completion of the study setup and confirmation of adequate anesthesia, the O2 concentration was changed to 21% and a tail vein catheter was inserted. After adequate catheter placement was confirmed, mice were administered a transfusion of either fresh, stored (36 -42 days) RBC, or "stored ϩ PIPA" RBCs over 60 s. Each mouse received a volume of 200 l packed human RBCs, roughly equivalent to a 2-unit transfusion of RBCs or ϳ10% blood volume (31) . All transfused RBCs were pre-exposed to the cell-membrane fluorescent marker PKH67 to facilitate microscopic RBC tracking and delineation of the vasculature (see below). After in vivo image collection at 21% O2 and 30 min, inhaled O2 was switched to 10% for another 30 min while images were collected again. At the end of experiments, mice were euthanized and their spleen harvested and weighed.
Imaging, fluorescent labeling, and detection of transfused RBCs (in vivo adhesion).
Washed RBCs were labeled with the fluorescent green dye PKH67 (Sigma) as previously described (42, 43), followed by washing with PBS. RBCs were examined under a fluorescent microscope fitted with a GFP filter.
Through the dorsal skin window, fluorescence microscopy was performed for visualization of PKH-green labeled transfused human RBCs. Images were collected on an inverted microscope (Zeiss) using a 5ϫ objective over a 2.2 ϫ 2.2 mm field of view, and acquired statically at 15 min posttransfusion during 21% O 2 exposure. This imaging sequence was repeated when the FiO2 level was changed to 10%. Datasets were collected over 10 s with continuous imaging (exposure time ϭ 30 ms). Images were stored digitally on a computer and analyzed offline for measurement of RBC adhesion.
To confirm the effects of hypoxia, images were acquired using a halogen brightfield source to acquire transmission images of the window chamber. A wavelength-tunable filter allowed for sequential collection of images over a wavelength range from 520 to 620 nm in 10-nm increments. A least-squares fit of the intensity across all wavelengths allowed for calculation of the optical absorption indicating the relative concentrations of oxy-and deoxyhemoglobin, thus yielding the Hb O 2 saturation throughout the window-chamber vasculature (28) .
Measurement of in vivo RBC adhesion was performed by examining video image sequences collected at 5ϫ magnification. RBC adherence was considered as any completely stationary, tagged (human) cell attached to the vascular wall for the entire duration of video sequence (323 frames over 10 s). The percentage adhesion was defined as the estimated number of nonmoving human RBCs/total number of human RBCs in an image ϫ 100. Total human RBC number was estimated by way of an initial determination of pixel area for a single cell and applied to the total region of interest area for all adherent RBCs. The total number of labeled RBCs for a given frame within an image sequence was determined by measuring pixel counts at a given fluorescent threshold intensity. All image processing was performed with ImageJ software.
Statistics. All values are reported as means Ϯ SE. Unless otherwise noted, analyses were performed using SigmaPlot (Systat Software, San Jose, CA). Specific hypothesis testing within each condition over time was performed using repeated-measures ANOVA. Data comparison at specific time points between conditions was made with unpaired t-tests, and the values within each condition were made with paired t-tests. Significance was set at P Ͻ 0.05.
RESULTS
RBC production of intracellular ATP during deoxygenation.
We first examined the impact of graded Hb deoxygenation on glycolytic flux in human RBCs. Intracellular ATP of fresh RBCs increased in dose-dependent fashion from 2.75 Ϯ 0.12 mol/g Hb during normoxia to 3.49 Ϯ 0.13, 4.53 Ϯ 0.18, and 5.35 Ϯ 0.25 mol/g Hb with progressively lower O 2 levels (Fig. 1A) . Consistent with previous reports (26, 33) , intracellular ATP content was significantly lower in sRBCs versus fRBCs in normoxia (1.73 Ϯ 0.06 vs. 2.75 Ϯ 0.13 mol/g Hb), and our present data further indicate a markedly reduced intracellular ATP content in sRBCs (vs. fRBCs) at each PO 2 studied ( Fig. 1A; 2 .02 Ϯ 0.05, 2.63 Ϯ 0.08, and 3.09 Ϯ 0.07 mol/g Hb). When the depressed normoxic intracellular ATP baseline is accounted for, the relative changes (increases) in ATP of sRBCs with progressive hypoxia were similar (Fig.  1B) , suggesting a significant defect in glycolytic flux in response to deoxygenation within stored RBCs. Supplementation with PIPA completely rescued the intracellular ATP content of sRBCs in normoxia (3.60 Ϯ 0.28 mol/g Hb), yielding levels slightly higher than those observed in fRBCs. In addition, PIPA treatment of sRBCs also improved ATP generation during Hb deoxygenation ( Fig. 1A; 4 .70 Ϯ 0.30, 5.72 Ϯ 0.44, and 6.58 Ϯ 0.68 mol/g Hb). Accordingly, the increase in intracellular ATP production to Hb deoxygenation within sRBCs was significantly blunted compared with fresh RBCs, but ATP production was intact in sRBCs pretreated with PIPA (Fig. 1B) .
Export of ATP from RBCs in response to deoxygenation. To determine whether RBC storage-induced deficits in ATP export could be ameliorated by treatment with PIPA, we mea- Fig. 2, A-C) . Basal ATP export from stored RBCs (4.8 5 Ϯ 0.33 nmol/4 ϫ 10 8 RBC) was lower than that from fRBCs and only significantly increased with deoxygenation at the lowest (ϳ15 mmHg) PO 2 . Furthermore, the absolute amount of ATP released was still significantly lower than that from fRBCs (5. Fig. 2A) . Deoxygenation of sRBCs pretreated with PIPA evoked significant increases in ATP export at both the moderate and severe hypoxia levels compared with untreated sRBCs (⌬2.22 Ϯ 0.57 and 3.93 Ϯ 0.67 vs. ⌬0.21 Ϯ 0.17 and 0.65 Ϯ 0.16 nmoles/4 ϫ 10 8 RBC; Fig. 2, B and C) . Importantly, hemolysis did not differ between groups and/or within conditions, nor was it directionally related to an increase in ATP export, consistent with evidence for genuine ATP export in response to deoxygenation (3, 7, 13, 15, 24, 36, 38, 41, 43) . The degree of hemolysis for each condition is as follows in the order from normoxia through lowest level of hypoxia: fRBCs, 0.041 Ϯ 0.014%, 0.026 Ϯ 0.007%, 0.04 Ϯ 0.009%, and 0.036 Ϯ 0.006%; sRBCs, 0.044 Ϯ 0.012%, 0.042 Ϯ 0012%, 0.046 Ϯ 0.013%, and 0.042 Ϯ 0.006%; PIPA-sRBCs, 0.086 Ϯ 0.035%, 0.10 Ϯ 0.044%, 0.07 Ϯ 0.023%, and 0.07 Ϯ 0.019%.
O 2 affinity of fRBCs, sRBCs, and PIPA-pretreated RBCs. By study design, a graded deoxygenation protocol allowed assessment of RBC Hb O 2 affinity through the creation of standard O 2 -dissociation curves and P 50 calculation. fRBCs had a P 50 of 28.3 Ϯ 0.3 mmHg, whereas sRBC O 2 affinity was significantly higher at 19.2 Ϯ 0.2 mmHg, with a leftward shift of the O 2 equilibrium curve (OEC; Fig. 3A ). As anticipated, PIPA greatly shifted the OEC further to the right, therefore significantly increasing the P 50 of sRBCs to 38.1 Ϯ 0.4 mmHg and demonstrating a genuine increase in RBC glycolytic flux with consequent production of the allosteric modulators ATP and 2,3 DPG. Such changes in P 50 (lower in sRBCs and higher in PIPA-treated sRBCs) are consistent with previous observations (2, 26, 27) .
In vivo adhesion of sRBCs and the impact of PIPA treatment. Inhalation of 10% F i O 2 markedly lowered the blood O 2 content as compared with 21% F i O 2 in nude mice (Fig. 4) . Fresh human RBCs were not substantially adherent to the microvasculature under normoxic or hypoxic stimuli (1.6 Ϯ 0.7 and 3.5 Ϯ 1.5%), but human RBCs within the last week of storage (36 -42 days) were significantly adherent, unlike fRBCs during both normoxia and hypoxia (15.6 Ϯ 2.3 and 21.4 Ϯ 2.8%; Fig. 5A ). PIPA-treated sRBCs (also 36 -42 days stored) were significantly less adherent than untreated sRBCs (normoxia: 4.5 Ϯ 0.7, hypoxia: 5.6 Ϯ 1.0%; Fig. 5A ). The increase in in vivo percent RBC adhesion from normoxia to hypoxia was significantly greater for sRBCs versus fRBCs (⌬5.8 Ϯ 0.7 vs. 1.8 Ϯ 0.9%), and this hypoxia-induced augmentation was blunted in PIPA-pretreated sRBCs (⌬1.1 Ϯ 1.6%; Fig. 5B ). To examine circulatory clearance of transfused RBCs by the recipient, spleen weight was examined. Recipient spleens were significantly heavier after transfusion with sRBCs than fRBCs (0.10 Ϯ 0.01 vs. 0.19 Ϯ 0.03 g). Spleens from mice transfused with PIPA-preteated sRBCs were not significantly heavier than those transfused with fRBCs, and were slightly less heavy than spleens from recipients receiving untreated stored RBCs (0.13 Ϯ 0.01 g; P ϭ 0.08; Fig. 6 ). Low O2 exposure elicited export of ATP from fRBCs, but not from sRBCs; however, PIPA pretreatment of sRBCs augmented ATP export at the lowest levels of PO2 (A). ATP export at a given level of hypoxia was blunted in stored (vs. fresh) RBCs, but pretreatment of sRBCs with PIPA significantly increased ATP export at the lowest PO2s (B). C: relation between extracellular ATP and O2 saturation across hypoxia levels within each RBC group. Note that impaired ATP export from sRBCs is independent of the elevated Hb O2 affinity and that improved ATP export from PIPA pretreatment is independent of reduced Hb O2 affinity. *P Ͻ 0.05 vs. 135 mmHg within condition; ‡P Ͻ 0.05 vs. untreated stored for a given PO2.
DISCUSSION
We present the first evidence that sRBCs are functionally defective in their glycolytic capacity to generate intracellular ATP during Hb deoxygenation stimulus and that this is associated with suppressed release of extracellular, anti-adhesive ATP. Moreover, we show that after transfusion, nearly expired banked human RBCs are substantially adherent to the vasculature in vivo, a response that is augmented under low O 2 conditions. Conversely, pretreatment of sRBCs with PIPA, a clinically accessible solution containing RBC metabolic precursors, promotes regulated export of ATP in response to Hb deoxygenation, and in turn suppresses RBC adhesion to the microvasculature in vivo under both normoxic and hypoxic conditions. Our findings indicate collectively that restoration of intracellular ATP and the release of ATP from sRBCs may be an effective strategy in efforts aimed to minimize transfusion-related cardiovascular complications while optimizing the benefit of transfusion.
The rationale for the present investigation stems from emerging evidence indicating that RBC transfusions for anemia are not always beneficial and in some patient groups may be associated with exacerbated injury and increased cardiovascular morbidity and overall mortality (5, 18) . Specifically, transfusion of human RBCs near the end of shelf-life (vs. Ͻ1 to 2 wk storage) has been linked to excess mortality and negative clinical outcomes, including organ failure (11, 12, 17, 19, 20) . Banking of RBCs elicits a multitude of deviations from RBC homeostasis, and although some changes are immediate, others evolve progressively over the 5-or 6-wk storage period (2) . Two commonly recognized lesions are the discernible drops in intracellular ATP and 2,3-DPG, both resulting from diminished glycolysis, and the consequential elevation in RBC Hb-O 2 affinity (2, 33). Therefore, we first investigated whether a functional defect in the sole energy-producing pathway of RBCs -glycolysis -could contribute, recognizing that glycolysis provides ATP and 2,3-DPG, which in turn regulate Hb-O 2 binding. To do so, isolated human RBCs were challenged with progressively lower O 2 concentration in an effort to elicit a deoxyHb-cdb3 interaction, and thus shift RBC metabolic dominance toward glycolysis (ATP generation) (4, 39) . Our results corroborate findings of decreased ATP content in sRBCs under basal conditions and show for the first time a marked defect in the ability of sRBCs to generate intracellular ATP when stimulated. These data collectively demonstrate an impaired glycolytic capacity within banked RBCs (Fig. 1) .
Given that all RBC samples were suspended in the same glucose-containing medium, a lack of glucose availability cannot explain our observations. In contrast, supplementation with a mixture rich in pyruvate, inosine, phosphate, and adenine by way of pretreating sRBCs with an additive solution that is "FDA-approved for special circumstances" (i.e., Rejuvesolequivalent or PIPA) fully overcame the storage-induced defect and allowed deoxygenation-induced increases in intracellular ATP to take place. Consequently, we speculate that long-term banking of RBCs may 1) severely suppress the activity of key glycolytic enzymes, which can then be rescued by high precursor concentration (i.e., concentration feed-forward control), 2) impair band 3-deoxy Hb interactions and subsequently either restrain the release of membrane-bound glycolytic enzymes, thus decreasing available enzyme concentration, or modulate key enzyme regulation (e.g., phosphorylation or allosteric control), or 3) increase ATP-dependent processes to such an extent that ATP consumption rates exceed the ATP accumulation rate. Regardless, our findings clearly demonstrate the inability of sRBCs to generate intracellular ATP to a level similar to that in fRBCs in response to low O 2 and that pretreatment with PIPA provides the means necessary for sRBCs to accumulate large quantities of intracellular ATP (Fig. 1) . Fig. 3 . Hb O2 affinity and the relation between intracellular ATP content and ATP export during RBC deoxygenation. Hb O2 affinity is greater in human sRBCs vs. fRBCs (left-shifted curve and lower P50), and PIPA pretreatment of sRBCs attenuated Hb O2 affinity (right-shifted curve and higher P50; A). Extracellular ATP released from fresh RBCs in response to deoxygenation is strongly associated with intracellular ATP production to low O2 (B). Extracellular ATP is related to intracellular ATP during hypoxia for all RBC groups. C: Although sRBCs treated with PIPA had a rescued capacity to export ATP in response to hypoxia, lower absolute levels of ATP were still present compared with those of fRBCs, indicating secondary impairment beyond solely intracellular ATP concentration. ‡P Ͻ 0.05 vs. stored for a given PO2.
RBCs can export ATP in a regulated fashion from within the intracellular space to the extracellular milieu. This response is in part dependent on the number of unoccupied Hb O 2 -binding sites; that is, ATP export follows Hb conformation rather than merely low PO 2 per se, consistent with evidence documenting impaired ATP export when cdb3 is inhibited (1, 3, 10, 13) . Although the export of extracellular ATP from RBCs is now well described, its relation to intracellular ATP content is not. Here we demonstrate in healthy fRBCs a very close relationship between intracellular ATP and the release of extracellular ATP in response to progressive Hb deoxygenation (r 2 ϭ 0.94; Fig. 3 , B and C). Our group recently documented a loss of regulated ATP release from sRBCs (43) , but as noted above, sRBCs have both depressed intracellular ATP content and a left-shifted OEC (thus less Hb T-state conformation for a given PO 2 and, consequently, less "stimulus" for release). In the present study, we exposed RBCs to varying degrees of low O 2 so as to produce overlapping fractional O 2 saturation curves. We demonstrate that sRBCs have blunted ATP export even when the Hb conformation is taken into account (Fig.  1C) , thus substantiating previous reports for impaired ATP export in these RBCs (41, 43) .
The hypoxia-induced increases in extracellular ATP we measured are consistent with genuine export of ATP and are unlikely the result of simple RBC lysis. Experimental protocols were rigorously and deliberately designed to curtail hemolysis (e.g., use of albumin in PSS and osmolality-controlled solutions) (15, 43) . Moreover, the resulting percent hemolysis values did not differ when gas concentrations were altered, nor was there a significant trend between percent hemolysis and the Color scaling on the far right demonstrates the percent Hb O2 saturation of blood within the microvascular network. HbO2 saturations Ͻ75% during normoxia are anticipated given O2 distribution in the microcirculation, anesthesia effects, and the high p50 of mouse RBCs (8, 14, 34) . FiO2, inspired O2 fraction. Nude mouse recipient spleen weight was significantly greater following transfusion of human sRBCs than fRBCs. Spleen weight was not significantly greater in PIPA pretreated sRBCs vs. fRBCs, and these treated RBCs were slightly lower than untreated sRBCs. †P Ͻ 0.05 vs. fresh. measured extracellular ATP within or across all RBC samples. Historic reports highlight that hemolysis must be thoroughly controlled to ensure the minimization of RBC rupture, therefore increasing detection capability and an unmasking of authentic ATP export (3). Along these lines, the recent publication by Sikora et al. (36) reemphasizes the need to stringently monitor hemolysis, although surprisingly, their limited study design did not specifically target approaches that safeguarded against hemolysis-induced increases in extracellular ATP, thus limiting generalization and interpretation of the investigation. Nonetheless, our present observations confirm those of numerous other investigators who have, like us, reported inducible and lysis-independent ATP export from intact, healthy human RBCs (3, 7, 13, 15, 24, 38, 41, 43) .
When compared with untreated sRBCs, PIPA-pretreated sRBCs had the expected decrease in O 2 affinity (Fig. 3A) , providing evidence for an increase in glycolytic flux and production of the intracellular allosteric modulators, ATP and 2,3-DPG. This directional shift in Hb allostery and consequent increase in deoxyHb could, in theory, independently augment ATP export for a given PO 2 (1, 13). However, increased ATP export from PIPA-treated RBCs was significant only at the two lowest percent O 2 exposures (Fig. 2) . These data in combination with the poor ability of sRBCs to export ATP at any O 2 saturation suggest that simply shifting Hb-O 2 affinity in the absence of robust glycolytic flux is not sufficient to promote marked ATP export. In addition, the present data show that ATP export by sRBCs pretreated with PIPA is quantitatively similar to that by fRBCs during moderate or severe hypoxia (Fig. 2B) . Of note however, despite this rectified exportation response from PIPA treated sRBCs during hypoxia, the absolute amount of extracellular ATP under basal normoxia or hypoxic stress never reached that seen from fRBCs (Fig. 2, A  and C) . These observations suggest a secondary defect unrectified by a combination of substantially lowered O 2 affinity and boosted intracellular ATP content for a given oxy-Hb fraction (Figs. 1C and 3C ). Given the key role for pannexin1 channels in ATP export from RBCs in response to deoxygenation (24, 38) , we previously considered whether sRBCs have less protein expression of pannexin1. However, protein abundance for pannexin1 does not decline during RBC banking (unpublished observations; TM and H. Zhu), therefore the secondary underlying mechanisms for impairment are unclear at this time. Nevertheless, PIPA supplementation is an effective means to rectify hypoxia-sensitive ATP export from sRBCs.
sRBCs have been implicated as more adherent than fRBCs (6, 21, 43) . Nevertheless, limited data exist describing the potential mechanism for such phenomena. Our group recently demonstrated that treating fRBCs with ATP export inhibitors or scavengers of extracellular ATP significantly augments RBC adhesivity to endothelial cells ex vivo, and conversely, that the addition of extracellular ATP attenuates RBC adhesion (43) . These data provide strong evidence that the loss of facile export of anti-adhesive ATP may be a mediator of the proadhesive effects of RBC storage. In the present study, we show that stored human RBCs pretreated with PIPA were less adherent to the microvasculature in vivo compared with untreated sRBCs in both normoxia and hypoxia (Fig. 5) . In addition, we observe that treatment of sRBCs can overcome the proadhesive effect of hypoxia (Fig. 5B) . Taken together, these findings indicate that PIPA improves intracellular ATP generation and facilitates an increase in extracellular ATP release from RBCs in response to hypoxia (Figs. 1 and 2 ).
We and others (21) observe attenuated adhesion of PIPAtreated sRBCs during normoxia, but the present study did not detect an elevation in basal ATP release from treated sRBCs. This could result from 1) a limited capacity to measure all ATP export, 2) the fact that RBCs are to some extent deoxygenating in vivo (in the microvascular network) even during normoxic gas exposure (Fig. 4), or 3) alternatively, that intracellular ATP concentrations are the key variable dictating vascular RBC adhesion rather than just release per se. In support of the latter proposition, the surface appearance of the adhesion molecule phosphatidylserine (PS) is negatively regulated by an ATPdependent flippase enzyme and increases during RBC banking, thus raising the possibility that PIPA reduced PS exposure in our studies. Other studies, however, suggest that although PIPA treatment augments intracellular ATP, this only partially modulates flippase and PS exposure (40) . We speculate that each of these factors might contribute. Regardless, we clearly observe that stored human RBCs pretreated with PIPA are not greatly adherent to the microvasculature in vivo.
In summary, we show for the first time that human RBCs stored for extended periods (to ϳ39 days) have disrupted glycolytic production of intracellular ATP coinciding with suppressed export of antiadhesive ATP, an impairment especially apparent during hypoxia. Despite this, presupplementing sRBCs with RBC metabolic precursors rescues deoxygenation-induced elevations in intracellular ATP and rectifies stimulated ATP export. Finally, we observe that microvascular adhesion of banked human RBCs is abundant in an in vivo setting and, moreover, significantly augmented during hypoxemia. Importantly, our novel observations demonstrate that pretreatment of RBCs with the substrate needed for augmented ATP synthesis (namely, ample glycolytic intermediate/purine/phosphate precursors, here as PIPA) before transfusion significantly suppresses RBC-vascular adhesion regardless of the oxygenation status of the recipient. Modulation of either the intracellular ATP content of RBCs or extracellular ATP export, or the combination, may prove beneficial in efforts intended to improve the balance between risk and benefit in anemic patients transfused with RBCs.
